‘That is an exciting opportunity for the drug development initiatives at UT Austin’s Texas Institute for Drug and Diagnostics Advancement. By partnering with the Gulf Coast Consortia, we are able to leverage capabilities and efforts in Austin with those of the Houston area institutions. Such an unprecedented degree of research coordination over the continuing state of Texas is an innovation in itself, one that will lead to an extremely fertile foundation for many breakthroughs in our fight against cancer,’ said Brent Iverson, Ph.D., the Warren J. And Viola Mae Raymer Professor and chairman of the Section of Chemistry and Biochemistry at UT Austin. Related StoriesNew RNA test of blood platelets can be used to detect location of cancerCornell biomedical engineers develop 'super organic killer cells' to destroy malignancy cells in lymph nodesNew antenna-like device makes breasts cancer surgery less difficult for surgeonsStephen Wong, Ph.D., the John S Dunn Distinguished Endowed Chair in Biomedical Engineering and professor of radiology, neurosciences, laboratory and pathology medicine at The Methodist Hospital Research Institute , added, ‘This enables us to become a hub and put Texas on the map in high throughput drug discovery nationally.The database held info on 14,440 ladies identified as having Stage I to IIIA hormone receptor-negative breast malignancy and 26,893 men and women diagnosed with Stage III colon cancer from 1992-2009. All subjects were over the age of 65. Among the women who had breast malignancy, chemotherapy treatment decreased the risk of death from all causes by thirty % for women age groups 65 to 69, 26 % for women ages 70 to 74 and 24 % for ladies ages 75 to 79. For women older than 80, chemotherapy didn’t reduce the risk of mortality significantly. However, when women older than 80 with breast cancer combined chemotherapy and an additional treatment, Adriamycin and cyclophosphamide, they experienced a 29 % reduced mortality risk.